Results 81 to 90 of about 27,411 (201)

Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives

, 2017
Hanford Yau,1 Mustafa Kinaan,2 Suzanne L Quinn,3 Andreas G Moraitis3 1Division of Endocrinology, Diabetes, and Metabolism, University of California, San Francisco (Fresno Division), Fresno, CA, USA; 2Division of Internal Medicine, University of Central ...
Quinn SL, Yau H, Moraitis AG, Kinaan M
core  

Adaptive vasodilatory response after octreotide treatment

, 2001
Despite the suppression of glucagon release, an adaptive response aimed at maintaining vasodilatation after octreotide treatment may exist in portal hypertension.
Fa-Yauh Lee, Ming-Chih Hou, Full-Young Chang, Shou-Dong Lee, Ying-Ying Yang, Yi-Tsau Huang, Tzung-Yan Lee, Han-Chieh Lin, Wui-Chiang Lee   +8 more
core   +1 more source

Use of octreotide for the treatment of protein‐losing enteropathy in dogs: Retrospective study of 18 cases

Journal of Veterinary Internal Medicine
Background More than 50% of dogs with protein‐losing enteropathy (PLE) fail to respond to standard therapies. Octreotide, a somatostatin analogue, is used in cases of intestinal lymphangiectasia (IL) in humans with some success.
Sara A. Jablonski, Allison S. W. Mazepa, M. Katherine Tolbert   +2 more
doaj   +1 more source

The Efficacy of Pharmacotherapy Intervention on Anthropometric Outcomes in Survivors of Childhood Brain Tumors: An Updated Systematic Review and Meta‐Analysis

Obesity Reviews, Volume 27, Issue 10, October 2026.
ABSTRACT Introduction Many survivors of childhood brain tumors face long‐term adverse health outcomes like obesity. Uncertainties surround the effect of interventions to manage obesity‐related outcomes in survivors of childhood brain tumors. The goal of this updated systematic review and meta‐analysis was to provide the best estimate of the treatment ...
David Hart, Lawrence Mbuagbaw, Joseph Beyene, Marwa Akola, Sarah Burrow, M. Constantine Samaan, Lehana Thabane, Adam Fleming, Donna L. Johnston, Shahrad R. Rassekh, Laura Banfield, Russell J. de Souza   +11 more
wiley   +1 more source

Subcutaneously Administered Self-Cleaving Hydrogel–Octreotide Conjugates Provide Very Long-Acting Octreotide

, 2016
We developed a long-acting drug-delivery system that supports subcutaneous administration of the peptidic somatostatin agonist octreotidea blockbuster drug used to treat acromegaly and neuroendocrine tumors. The current once-a-month polymer-encapsulated
Gary W. Ashley (1653217), Daniel V. Santi (59082), Ralph Reid (59081), Jeff Henise (1653220), Eric L. Schneider (263886)   +4 more
core   +1 more source

Comparative analysis of adverse event profiles of lanreotide and octreotide in somatostatin-responsive endocrine and neoplastic diseases

Scientific Reports
Lanreotide and Octreotide are used to treat various endocrine and neoplastic diseases. This study aims to compare the adverse event profiles of Lanreotide and Octreotide in somatostatin-responsive diseases using FAERS data.
Le Wang, Shenglin Chen, Mengying Wu, Lijuan Zhou   +3 more
doaj   +1 more source

Octreotide-Conjugated Core-Cross-Linked Micelles with pH/Redox Responsivity Loaded with Etoposide for Neuroendocrine Neoplasms Therapy and Bioimaging with Photoquenching Resistance

, 2019
The study of multifunctional polymer micelles combined with chemotherapy due to reduced systemic toxicity and enhanced efficacy has attracted intensive attention.
Min Liu, Yun Shao (840301), Bingyan Xue, Min Liu (45756), Qiyun Tang (124659), Fangzhou Liu, Xintong Lu (6671168), Qiyun Tang, Guoqin Zhu (6671171), Bingyan Xue (6671174), Ping Hu (59156), Jintian Wang, Jintian Wang (6655883), Na He (295300), Xiaolin Li (397893), Ping Hu, Jianan Bai, Guoqin Zhu, Xiaolin Li, Yun Shao, Jianan Bai (6671165), Xintong Lu, Ye Tian, Ye Tian (220278), Na He, Fangzhou Liu (1743835)   +25 more
core   +1 more source

Octreotide [PDF]

Journal of Pain and Symptom Management, 2010
Eva, Murphy, Eric E, Prommer, Mary, Mihalyo, Andrew, Wilcock   +3 more
openaire   +2 more sources

Pre-clinical comparison of [DTPA⁰] octreotide, [DTPA⁰,Tyr³] octreotide and [DOTA⁰,Tyr³] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy

, 1998
We have evaluated the potential usefulness of radiolabelled [DTPA0,Tyr3]octreotide and [DOTA0,Tyr3]octreotide as radiopharmaceuticals for somatostatin receptor-targeted scintigraphy and radiotherapy.
Bakker, Willem H., Visser, Theo J., Srinivasan, Ananth, Breeman, Wout A.P., Hofland, Leo J.; id_orcid, Bernard, Bert F., Mäcke, Helmut R., Béhé, Martin, Schmidt, Michelle, Krenning, Eric P., De Jong, Marion   +10 more
core   +1 more source

Prophylactic octreotide for pancreatoduodenectomy: more harm than good? [PDF]

, 2014
BackgroundMost accrued evidence regarding prophylactic octreotide for a pancreatoduodenectomy (PD) predates the advent of the International Study Group of Pancreatic Fistula (ISGPF) classification system for a post-operative pancreatic fistula (POPF ...
Vollmer, Charles M., Drebin, Jeffrey A., Kent, Tara S., McMillan, Matthew T., Christein, John D., Behrman, Stephen W., Callery, Mark P., Lewis, Russell S., Miller, Benjamin C.   +8 more
core   +1 more source